Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.
Roger R. Dmochowski, MD, MMHC, FACS
Advertisement
Articles by Roger R. Dmochowski, MD, MMHC, FACS
Nearly 60% of patients taking vibegron remained on treatment at 1 year.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
